Overview

* Soleno Q2 product revenue $32.7 mln, first revenue from VYKAT XR

* Company reports Q2 net loss of $4.7 mln despite revenue generation

* Raised $230 mln in stock offering post-Q2, boosting cash reserves

Outlook

* Soleno expects selling, general and administrative expenses to increase post-VYKAT XR commercialization

Result Drivers

* VYKAT XR LAUNCH - Generated $32.7 mln in product revenue following U.S. launch in April 2025

* PATIENT STARTS - Received 646 patient start forms and 295 unique prescribers for VYKAT XR

* MARKETING EXPENSES - Increased selling, general and administrative expenses due to commercial launch activities

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS -$0.09

Q2 Net -$4.71

Income mln

Q2 Basic -$0.09

EPS

Q2 $39.18

Operatin mln

g

Expenses

Q2 -$6.52

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Soleno Therapeutics Inc ( SLNO ) is $115.00, about 29% above its August 5 closing price of $81.63

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)